Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Neoplasms
Interventions: DRUG: Cisplatin|DRUG: Gemcitabine|DRUG: Anetumab ravtansine (BAY94-9343)
Sponsor: Bayer
Collaborators: ImmunoGen, Inc.|MorphoSys AG